X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OLX-07010 is an oral, small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade, a process believed to be implicated in the development of Alzheimer’s disease and other neurodegenerative disorders.
Lead Product(s): OLX-07010
Therapeutic Area: Neurology Product Name: OLX-07010
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
OLX-07010 would potentially fill a significant unmet need with a disease-modifying drug that, if successful, will have a tremendous impact on patient outcomes and reduce the burden on caregivers and society.
Lead Product(s): OLX-07010
Therapeutic Area: Neurology Product Name: OLX-07010
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Aging
Deal Size: $3.4 million Upfront Cash: Undisclosed
Deal Type: Funding August 09, 2022
Details:
The lead candidate OLX07010, has demonstrated efficacy in animal models of tau-mediated neurodegeneration. Preclinical safety studies are completed and Phase 1a clinical studies are planned to initiate in the third quarter of 2022.
Lead Product(s): OLX07010
Therapeutic Area: Neurology Product Name: OLX-07010
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 03, 2022
Details:
A study was conducted in the tau P301L JNPL3 mouse model for tau aggregation and motor impairment that was aged prior to treatment in order to study the therapeutic effect of OLX-07010.
Lead Product(s): OLX-07010
Therapeutic Area: Neurology Product Name: OLX-07010
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
OLX07010, has demonstrated efficacy in several animal models of neurodegeneration and, upon completion of its preclinical program in the next couple of months, will start Phase 1 clinical studies in early 2022.
Lead Product(s): OLX07010
Therapeutic Area: Neurology Product Name: OLX07010
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2021
Details:
Company will be presenting preclinical data on its oral, tau self-association small molecule inhibitor lead program, OLX-07010, at the 2021 Alzheimer's Association International Conference.
Lead Product(s): OLX-07010
Therapeutic Area: Neurology Product Name: OLX-07010
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
Poster titled "Therapeutic efficacy of a small molecule inhibitor targeting tau self-association in mouse models of tauopathy" will be presented at the 13th Clinical Trials on Alzheimer’s Disease Conference 2020 Digital Event.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
